Genus, Meet Species: Court Weighs Novo Nordisk’s Semaglutide Patent
Novo Nordisk A/S took Dr Reddy's Laboratories to the Delhi High Court over its Semaglutide patent, seeking to block generic imports of the anti-diabetic drug. Would the court…
44 articles
Novo Nordisk A/S took Dr Reddy's Laboratories to the Delhi High Court over its Semaglutide patent, seeking to block generic imports of the anti-diabetic drug. Would the court…
Titan Company Limited took its rejected “Jewellery Assembly” application to the Madras High Court, testing whether a cost-saving gemstone arrangement was patent or design subject matter. Did the…
The Delhi High Court sets aside the Controller’s blanket refusal of an FTIR spectral analysis patent for skin cancer tissue characterization, holding that the Controller misapplied the Section…
The Delhi High Court's Division Bench held that product-to-claim mapping is indispensable for patent infringement, even in anticipatory suits. In a dispute between Zydus Lifesciences and E.R. Squibb…
Daewoong Pharmaceutical challenged the Controller's rejection of its crystalline SGLT inhibitor patent before the Delhi High Court. The core question: does improved dissolution and stability satisfy the Section…
Philip Morris Products S.A. challenged eight patent refusals at the Delhi High Court, each rejected by the Controller under Section 3(b) of the Patents Act on the ground…
The Bombay High Court refused to summarily dismiss patent infringement suits filed by Bharat Bhogilal Patel against TVS Electronics Ltd. and Kalelkar Surgicals Pvt. Ltd., holding that two…
When Neurocentria Inc. sought to revive its Indian patent application by disclaiming its earliest PCT priority date - effectively restarting the clock on missed deadlines; the Delhi High…
In suits filed as far back as 2009, Koninklijke Philips claimed its DVD decoding patent was a standard essential patent infringed by two Delhi-based manufacturers. The Single Judge…
The Bombay High Court, in AIC246 AG & Co. KG v. The Patent Office of India, has set aside a patent rejection that bypassed the mandatory Section 14…